TIPS treatment support for liver cancer patients on Atezo + Bev
Part of Cancer, Digestive system clinical trials.
This study looks at whether adding TIPS (a procedure to reduce fluid buildup) to standard immunotherapy (atezolizumab and bevacizumab) helps people with advanced liver cancer who also have cirrhosis. It's for patients whose cancer cannot be removed by surgery or has progressed after other local treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (HCC) that has spread or cannot be removed by surgery.
- You have liver cirrhosis (scarring of the liver).
- Your doctor has already decided to treat you with atezolizumab and bevacizumab (with or without TIPS).
- You can start or have already had 1-2 cycles of this drug combination.
- You are 18 years or older.
- You can understand and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TPST-1120 combined with two standard treatments (atezolizumab and bevacizumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this combination works better than the standard approach alone.
This trial tests combining three drugs (atezolizumab, bevacizumab, and tocilizumab) to see if they can help people with advanced liver cancer that cannot be removed with surgery. It aims to shrink tumors and improve outcomes for patients who have not had prior systemic therapy.
This study tests a combination of a liver-directed treatment (TACE) with two immunotherapy drugs and bevacizumab for patients with liver cancer that cannot be surgically removed but has not spread outside the liver. The goal is to see if this approach can shrink tumors and improve outcomes.
This study looks at how well the combination of atezolizumab and bevacizumab works for people with liver cancer that has come back or spread, based on real patient records from a hospital registry.
This Phase 2 trial tests whether starting with atezolizumab plus bevacizumab, then using an on-demand TACE (a targeted liver artery chemo treatment) can control hepatocellular carcinoma (liver cancer). It also compares this approach to giving both medicines together with an initial TACE right away, aiming to improve tumor control and outcomes.
This trial studies whether a combination of immune therapy (atezolizumab) and a blood-vessel-targeting drug (bevacizumab) works better than a standard procedure called TACE for people with intermediate-stage liver cancer (HCC). It may help shrink tumors and help patients live longer with fewer complications.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.